Recent work has shown that in vivo treatment with saroglitazar, a PPARα/PPARγ agonist, is associated with reduced inflammation and regression of fibrosis in experimental NASH models (198). Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.